Navigation Links
Pfizer Oncology To Present New Clinical Data Across Ten Tumor Types and Multiple Molecular Targets
Date:10/7/2010

red Paper session (Abstract #1344O, October 10).(7)

Pfizer continues to investigate approved therapies within its portfolio, including Aromasin® (exemestane tablets).  At the Congress, research findings for the compound will be presented in two key presentations.

- Distant recurrences at median of 5-years among 9,779 postmenopausal women with hormone receptor-positive early breast cancer treated on the TEAM trial of adjuvant endocrine therapy (Abstract #213O, October 11)(8)

- Effects of exemestane or tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial: a meta-analysis (Abstract #225P, October 10)(9)

Data on the following compounds and investigational agents will also be presented: neratinib (HER2 positive breast, solid tumors),(10),(11) axitinib (renal cell carcinoma or RCC),(12) inotuzumab (non-Hodgkin's lymphoma),(13) and Torisel® (temsirolimus) (RCC, solid tumors).(14),(15)

For more news and information, follow Pfizer Oncology at ESMO through Twitter @pfizer_news (http://twitter.com/pfizer_news).

About Sutent® (sunitinib malate)

Sutent is an oral multi-kinase inhibitor approved for the treatment of advanced RCC and for the treatment of GIST after disease progression on or intolerance to imatinib mesylate.

Sutent works by blocking multiple molecular targets implicated in the growth, proliferation and spread of cancer.  Two important Sutent targets, vascular endothelial growth factor receptor (VEGFR) and platelet-derived growth factor receptor (PDGFR), are expressed by many types of solid tumors and are thought to play a crucial role in angiogenesis, the process by which tumors acquire blood vessels, oxygen and nutrients needed for growth.  Sutent also inhibits other targets important to tumor growth, including KIT, FLT3 and RET.

I
'/>"/>

SOURCE Pfizer Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Wyeths Torisel and Roche/Genentechs Avastin Will Challenge Pfizers Sutent to Become the Clinical Gold Standard for Treatment of Metastatic Renal Cell Carcinoma
2. Kosans Motilin Receptor Agonist, Licensed to Pfizer, Enters Phase 1 Clinical Trial in Gastroesophageal Reflux Disease
3. Coley Pharmaceutical Group and Pfizer Nominate Additional Anti-Cancer Compound for Clinical Development
4. Rigel Announces Initiation of Phase 1 Clinical Trial of R343 for Allergic Asthma by its Partner Pfizer
5. NicOx Announces Pfizer Initiates Phase 2 Clinical Development for PF-03187207 in Japan
6. Tacere Therapeutics Enters Collaboration and License Agreement With Pfizer To Develop and Commercialize RNAi Hepatitis C Drug
7. MannKind Addresses Pfizers Announcement Regarding Exubera
8. Quark Pharmaceuticals Announces First Patient Dosing by Pfizer in Phase II Trial of RNAi Therapy in Diabetic Macular Edema
9. Silence Therapeutics to Receive $1.9m Milestone Payment as Pfizer and Quark Commence Phase II Trial
10. Medarex Receives Milestone Payment from Pfizer for Investigational New Drug Application Filing
11. Pfizer Contributes Critical Data to URMC Drug Safety Initiative
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2013)... MECHELEN, Belgium , May 17, 2013 ... ABBV ) announced today an extension of their GLPG0634 ... fund and complete a Phase 2 program in Crohn,s ... Phase 3.  Upon successful completion of the study, expected ... The terms of the collaboration extension are in addition ...
(Date:5/16/2013)... May 16, 2013  Nektar Therapeutics, (Nasdaq: NKTR ... Robin , is scheduled to present at the upcoming ... at the Sheraton New York Hotel on Tuesday, ... The presentation will be accessible via a Webcast through a ... the Nektar website: http://www.nektar.com . This Webcast will be ...
(Date:5/16/2013)... and SYDNEY , May 16, 2013 /PRNewswire/ ... HIN), a leading innovator of less invasive, miniaturized circulatory support ... today announced that CEO Doug Godshall ... Conference at 11:00 a.m. EDT on Monday, May 20, 2013.  ... Sheraton New York Hotel. A live webcast of ...
Breaking Medicine Technology:AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 2AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 3AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 4AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 5AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 6Nektar Therapeutics' President and CEO, Howard W. Robin, To Present at the 2013 UBS Global Healthcare Conference in New York City 2HeartWare Presentation At The 2013 UBS Global Healthcare Conference To Be Webcast 2
(Date:5/19/2013)... Springs, FL (PRWEB) May 19, 2013 Omaha, ... It is also a city with one of the lowest ... ranking it eleventh in their Best Places for Business and ... for Relocation lists. Omaha is centrally located in the ... stalwarts of industry located there. The producers of Editions ...
(Date:5/19/2013)... (PRWEB) May 19, 2013 Actos ... federal litigation now underway in U.S. District Court, Western ... Order dated May 3rd, the Court has modified the ... to eight cases rather than four. The next Status ... Thursday, May 23rd. (In re: Actos Product Liability Litigation, ...
(Date:5/19/2013)... California (PRWEB) May 19, 2013 Grinding ... than just losing sleep, or annoying your spouse. At ... report by CNY Central (“Snoring and Teeth Grinding Could ... type of teeth grinding can be hard to prevent. ... million Americans, and one of its symptoms is a ...
(Date:5/19/2013)... 19, 2013 These molecular diagnostics ... UK, Spain, Japan, Italy, Germany and France:, ... diagnostics laboratory practice, as well as key economic, ... market impact during the next five years. , ... biochip technologies, test formats, detection methodologies, trends in ...
(Date:5/19/2013)... York, New York (PRWEB) May 19, 2013 ... that a Case Management Conference was recently convened for ... a federal multidistrict litigation now underway in U.S. District ... posted on the Court’s website on May 14th, the ... It was also reported during the Conference that ...
Breaking Medicine News(10 mins):Health News:Editions TV Announces May Air Dates for Omaha, Nebraska 2Health News:Actos Lawyers at Bernstein Liebhard LLP Note Issuance of New Case Management Order in Federal Actos Bladder Cancer Litigation 2Health News:Actos Lawyers at Bernstein Liebhard LLP Note Issuance of New Case Management Order in Federal Actos Bladder Cancer Litigation 3Health News:Dr. Kanani, Woodland Hills Dentist: Dangers of Tooth Damage and Obstructive Sleep Disorder 2Health News:Dr. Kanani, Woodland Hills Dentist: Dangers of Tooth Damage and Obstructive Sleep Disorder 3Health News:Molecular Diagnostics Market - US, UK, Spain, Japan, Italy, Germany & France Analysis in New Research Report at ReportsnReports.com 2Health News:Molecular Diagnostics Market - US, UK, Spain, Japan, Italy, Germany & France Analysis in New Research Report at ReportsnReports.com 3Health News:Molecular Diagnostics Market - US, UK, Spain, Japan, Italy, Germany & France Analysis in New Research Report at ReportsnReports.com 4Health News:Pradaxa Lawyers at Bernstein Liebhard LLP Report on Recent Status Conference in Federal Pradaxa Litigation 2Health News:Pradaxa Lawyers at Bernstein Liebhard LLP Report on Recent Status Conference in Federal Pradaxa Litigation 3
... have lower risks of Alzheimer,s disease and other cognitive ... In more than half of the studies, published since ... had lower dementia risks than nondrinkers. In only a ... a two-edged sword," said Michael Collins, Ph.D., a professor ...
... Review Examines All Aspects of Hospital OperationsCAMBRIDGE, Mass., ... survey of Cambridge Health Alliance by The Joint ... safety and quality of health care in the ... CHA,s chief executive officer, and "is the best ...
... bid to force TomoTherapy to consider strategic alternativesMADISON, Wis., Dec. ... Capital Group, announced that on December 23, 2008 it nominated ... Inc. (Nasdaq: TOMO ). This step is the ... for the company,s shareholders in the wake of the precipitous ...
... Mich., Dec. 29 Versus Technology,Inc. ("Versus" or ... year ended Oct. 31, 2008, compared to revenues ... the fiscal quarter ended Oct. 31, 2008, were,$1,748,000 ... period in 2007.,Versus, quarterly revenues can vary significantly ...
... Hebrew University of Jerusalem have succeeded in reversing brain birth ... brain cells. , The work of Prof. Joseph Yanai ... presented at the Tel Aviv Stem Cells Conference last spring ... at the seventh annual meeting of the International Society ...
... 29 After retiring from a night-shift job 12 years ... on TV shows, including Monday Night Football. He also ate ... caught up with him: He became overweight and was diagnosed ... when he knew he had to change his lifestyle."It was ...
Cached Medicine News:Health News:Moderate drinking can reduce risks of Alzheimer's dementia and cognitive decline 2Health News:Joint Commission Reports Positive Survey Results for CHA 2Health News:Joint Commission Reports Positive Survey Results for CHA 3Health News:Avalon Portfolio Nominates Slate of Directors for TomoTherapy Board 2Health News:Avalon Portfolio Nominates Slate of Directors for TomoTherapy Board 3Health News:Versus Technology Announces Fiscal Year Results 2Health News:Versus Technology Announces Fiscal Year Results 3Health News:Versus Technology Announces Fiscal Year Results 4Health News:Versus Technology Announces Fiscal Year Results 5Health News:Versus Technology Announces Fiscal Year Results 6Health News:Versus Technology Announces Fiscal Year Results 7Health News:Hebrew University scientists succeed through stem cell therapy in reversing brain birth defects 2Health News:African Americans to Reach Health Resolutions Through Search Your Heart 2
Fine pointed grooved jaws with smooth curve from tip to finger grip style handle. Dull finish....
Inner jaw space 2.0 mm - 45 degree tip angulation. 20 gauge (.89 mm) diameter shaft and stationary distal jaw. Lightweight squeeze handle with dull finish. Jaws 1.5 mm serrated....
Straight shafts with 5.5 mm tying platform and 45 degree 0.3 mm teeth. Wide serrated handle with polished finish....
Straight shafts with 1 x 2 teeth. Flat handle with polished finish....
Medicine Products: